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Abstract 
Background. Depression and major depressive disorder affect 25% of the population. First line treatment 
utilizing selective serotonin reuptake inhibitors (SSRIs) have met with limited success due to well-
recognized negative side effects which include weight gain or loss. This inability to control unwanted side 
effects often result in patients stopping their antidepressant medications. The mechanisms underlying 
the failure of SSRIs are incompletely understood. 
Methods. Male CF-1 mice (5 weeks of age, N D 10 per group) were per orally administered fluoxetine (20 
mg per kg body weight) or diluent daily for 29 days. During this time fecal specimens were collected at 
three defined time points (0, 15 and 29 days). At the conclusion of the 29-day dosing regimen, animals 
were subjected to two behavioral assessments. For bacterial identification of the microbiota, 16S rRNA 
gene sequencing was performed on 60 fecal specimens (three specimens per mouse time course, N D20 
mice) using Illumina MiSeq. Analysis of community sequence data was done using mothur and LEfSe 
bioinformatic software packages. 
Results. Daily per oral administration of fluoxetine for 29 days to male mice resulted in a significant, time 
dependent, alteration in microbial communities accompanying changes in body weight. The calculated 
species richness and diversity indicators of the murine fecal microbial communities were inconsistent 
and not significantly different between the groups. Among the phylotypes decreased in abundance due to 
fluoxetine administration were Lactobacillus johnsonii and Bacteroidales S24-7 which belong to phyla 
associated with regulation of body mass. The observed changes in body weight due to fluoxetine 
administration mimicked the dramatic shifts in weight gain/loss that has been observed in humans. 
Further, at the conclusion of the 29-day dosing regimen fluoxetine-dosed animals evidenced a mild 
anxiogenic-like behavior. 
Discussion. We report that the most widely used antidepressant, fluoxetine, which is an SSRI-type drug, 
results in the selective depletion of gut microbiota, specifically the Lactobacilli which are involved in the 
regulation of body weight. Concomitantly, fluoxetine administration increases the abundance of 
phylotypes related to dysbiosis. Since Lactobacilli have been previously shown to possess a known 
biogenic amine transporter that regulates the uptake of fluoxetine, it is proposed that a microbial 
endocrinology-based mechanistic pathway is responsible for the ability of SSRIs to selectively negatively 
impact beneficial microbiota. The results of this study therefore suggest that the negative clinical side 
effects due to fluoxetine administration may be due to alterations in gut microbiota. Further, the data also 
suggests that supplementation of bacterial genera directly affected by fluoxetine administration may 
prove useful in ameliorating some of the well-known side effects of chronic fluoxetine administration 
such as weight alterations. 
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ABSTRACT
Background. Depression and major depressive disorder affect 25% of the population.
First line treatment utilizing selective serotonin reuptake inhibitors (SSRIs) have met
with limited success due to well-recognized negative side effects which include weight
gain or loss. This inability to control unwanted side effects often result in patients
stopping their antidepressant medications. The mechanisms underlying the failure of
SSRIs are incompletely understood.
Methods. Male CF-1 mice (5 weeks of age, N = 10 per group) were per orally
administered fluoxetine (20mg per kg body weight) or diluent daily for 29 days. During
this time fecal specimens were collected at three defined time points (0, 15 and 29
days). At the conclusion of the 29-day dosing regimen, animals were subjected to two
behavioral assessments. For bacterial identification of the microbiota, 16S rRNA gene
sequencing was performed on 60 fecal specimens (three specimens per mouse time
course,N = 20 mice) using Illumina MiSeq. Analysis of community sequence data was
done using mothur and LEfSe bioinformatic software packages.
Results. Daily per oral administration of fluoxetine for 29 days to male mice resulted
in a significant, time dependent, alteration in microbial communities accompanying
changes in body weight. The calculated species richness and diversity indicators of the
murine fecal microbial communities were inconsistent and not significantly different
between the groups. Among the phylotypes decreased in abundance due to fluoxetine
administration were Lactobacillus johnsonii and Bacteroidales S24-7 which belong to
phyla associated with regulation of body mass. The observed changes in body weight
due to fluoxetine administration mimicked the dramatic shifts in weight gain/loss that
has been observed in humans. Further, at the conclusion of the 29-day dosing regimen
fluoxetine-dosed animals evidenced a mild anxiogenic-like behavior.
Discussion. We report that the most widely used antidepressant, fluoxetine, which
is an SSRI-type drug, results in the selective depletion of gut microbiota, specifically
the Lactobacilli which are involved in the regulation of body weight. Concomitantly,
fluoxetine administration increases the abundance of phylotypes related to dysbiosis.
Since Lactobacilli have been previously shown to possess a known biogenic amine
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transporter that regulates the uptake of fluoxetine, it is proposed that a microbial
endocrinology-based mechanistic pathway is responsible for the ability of SSRIs to
selectively negatively impact beneficial microbiota. The results of this study therefore
suggest that the negative clinical side effects due to fluoxetine administrationmay be due
to alterations in gut microbiota. Further, the data also suggests that supplementation
of bacterial genera directly affected by fluoxetine administration may prove useful in
ameliorating some of the well-known side effects of chronic fluoxetine administration
such as weight alterations.
SubjectsMicrobiology, Neuroscience, Psychiatry and Psychology
Keywords Fluoxetine, SSRIs, Depression, Lactobacillus, Microbial communities,
Microbiota-gut-brain axis
INTRODUCTION
The failure of drug therapy to adequately treat depression in large segments of the
population and the numerous side effects that accompany its chronic administration
such as anxiogenic effects and changes in body weight has been well recognized for years in
both human (Anderson, 1998; Cascade et al., 2010) as well as animal populations (Aggarwal
et al., 2016; Bagdy et al., 2001). Antidepressants, notably the selective serotonin reuptake
inhibitors , otherwise referred to as SSRIs, are considered the first line of treatment for
anxiety and major depressive disorder (Williams et al., 2017). SSRIs, as with the great
majority of drugs, are taken per orally. Although the pharmacokinetic analysis of per oral
dosing of SSRIs has demonstrated that the majority is absorbed into the host with peak
plasma concentration occurring within 4–6 h following, a significant percentage of the
administered per oral dose can in fact be recovered in the feces as has been shown in
human volunteers (Lemberger et al., 1985). Thus, in addition to the host, the microbiota
also represents a biological entity that interacts with any administered drug such as SSRIs.
However, a crucial difference is that far less is known concerning the consequences of
antipsychotic drug-microbiota interactions than are known for the host. Little, if any,
research has been done on the mechanisms governing the effects of antidepressants on
the microbiota and whether the failure and side effects of antidepressant therapy may be
due to altered drug-induced microbiota. That it is entirely plausible that the microbiota
composition, and in turn function, can be influenced by oral antipsychotic drugs can be
seen in published evidence that has shown that among the large diversity of non-antibiotic
drugs administered within the general population, antipsychotic drugs had potent effects
on fecal microbial diversity (Maier et al., 2018). Additionally, a recent study analyzed the
effect of fluoxetine on gut microbiota in rats (Cussotto et al., 2018), but so far, the effect of
fluoxetine on gastrointestinal tract microbiota composition remains largely unknown.
In proposing a direct microbial effect of SSRIs, we have employed a microbial
endocrinology-based theoretical framework as it has as its basis the concept of shared
neurochemistry between microbes and host enabling bi-directional communication
(Lyte, 2014). This approach has led to the recent discovery that selective bacterial genera
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within the gut microbiota, such as the Lactobacilli, possess the same two biogenic amine
transports which are found in mammalian neuronal cells and are intimately involved in
the therapeutic action of SSRIs (Lyte & Brown, 2018). The plasma membrane monoamine
transporter (PMAT)- and the organic cation transporter (OCT)-like were shown to be
present in Lactobacillus salivarius, but not L. rhamnosus, and display similar activity in
regard to reuptake inhibitors such as the SSRI fluoxetine as is observed in mammalian
neuronal cell cultures (Lyte & Brown, 2018).
As such, we hypothesized that per oral, chronic administration of fluoxetine could
influence the diversity of the gut microbiota through direct microbial endocrinology-based
interactions. This interaction would, by definition, be specific to only those bacterial genera
which exhibit cell-based mechanisms, such as biogenic amine transporters, with which
to interact with fluoxetine. This differs from previous reports which extend back decades
that have reported that a number of psychoactive drugs can negatively influence bacterial
viability and even suggested as an adjunct to therapy of a number of infectious diseases
as the addition of an SSRI could lower the minimum inhibitory concentration of an
antimicrobial with certain multi-drug resistant pathogens (Munoz-Bellido, Munoz-Criado
& Garcia-Rodriguez, 1996; Munoz-Bellido, Munoz-Criado & Garcia-Rodriguez, 2000). The
present study was designed to examine if a genus-specific effect of fluoxetine administration
could be shown. If so, it then would become plausible to suggest that the ability of fluoxetine
to influence host behavior as well as engender unwanted side effects could be due to direct
microbial endocrinology-based effects within the host gut microbiota.
MATERIALS AND METHODS
Animals
Twenty male CF-1 mice at 5 weeks of age (Charles River Laboratories, Wilmington,
MA, USA) were randomized upon receipt and then housed at a density of 2 per cage
(McCafferty et al., 2013). All experimental procedures were approved by the Iowa State
University Institutional Animal Care and Use Committee, protocol #1-17-8420-M. Mice
were weighed every other day in order to ensure that the correct mg per kg dosage was being
administered. As shown (Fig. 1), body weight changed rapidly in response to fluoxetine
administration.
Drug administration
Fluoxetine (TCI Chemicals, product #F0750, Portland, OR, USA) was initially dissolved
in PBS at a concentration of 5 mg per ml. The resulting stock fluoxetine solution, as
well as the diluent PBS, was then frozen in separate aliquots at −80 ◦C to provide for
consistent solutions that were used for daily dosing. On the day of dosing, individual
aliquots were thawed and administered to mice by gavage (flexible plastic feeding needles
#9921, Cadence Science, Cranston, RI, USA) to achieve a concentration of 20 mg per kg
body weight with equal volumes of diluent administered to control animals. This dosage
was selected according to the landmark study of Dulawa et al. (2004) which evaluated the
dose response relationship of chronic per oral fluoxetine administration in four strains of
mice over an approximately 24 day period in various models of anxiety and depression
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Figure 1 (A)Weight changes over time in control and fluoxetine-dosed mice (N = 10 per group) and
(B) Percent changes in bodyweight over time in control and fluoxetine-dosed animals (N = 10 per
group). Statistical analyses were conducted and p values are shown in the figure (two-tailed t tests).
Full-size DOI: 10.7717/peerj.6199/fig-1
and determined that 18 mg per kg body weight was found to be active in all behavioral
paradigms.
Behavioral procedures
At the conclusion of the 29-day dosing regimen, two behavioral assessments, elevated-plus
maze (EPM) and open field (OF), were conducted. These tests have been well-characterized
to measure anxiety-like behavior in mice (Prut & Belzung, 2003; Walf & Frye, 2007). All
movement and behavioral activity on the EPM and OF was digitally recorded using an HD
1,080 p webcam (Logitech, Newark, CA) coupled to a Windows-based computer running
the Any-maze behavioral tracking software (Stoelting Co., Wood Dale, IL, USA). Statistical
analyses of the behavioral data was performed using GraphPad Prism statistical software
package (version 7.05, GraphPad Software, La Jolla, CA, USA).
DNA isolation, MiSeq sequencing and sequence analyses
Immediately following the last behavioral measure, mice were sacrificed via cardiac
puncture. Fecal pellets were removed from the large intestine and from the behavioral
testing device immediately prior to sacrifice and stored at−80 ◦C. Genomic DNA isolation
was obtained using the PowerSoil DNA Isolation Kit (MoBio, Carlsbad, CA, USA).
In total, 60 fecal samples, representing 20 samples for each time point (day 0, 15,
and 29) with 10 samples for the control and treatment groups, respectively, were used
for 16S rRNA gene amplicon sequencing using Illumina MiSeq with 151 bp paired-end
sequencing technology. 16S rRNA gene PCR and library preparation and sequencing was
completed at the Environmental Sample Preparation and Sequencing Facility at Argonne
National Laboratory. For Illumina sequencing, Genomic DNA was amplified using the
Earth Microbiome Project barcoded primer set, adapted for the Illumina MiSeq by adding
nine extra bases in the adapter region of the forward amplification primer that support
paired-end sequencing. The V4 region of the 16S rRNA gene (515F-806R) was amplified
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with region-specific primers that included the Illumina flowcell adapter sequences. The
reverse amplification primer contained a twelve base barcode sequence. Each 25 µl PCR
reaction contained 12 µl of MoBio PCR Water (Certified DNA-Free), 10 µl of 5 Prime
HotMasterMix (1×), 1 µl of Forward Primer (5 µM concentration, 200 pM final), 1 µl
Golay Barcode Tagged Reverse Primer (5 µM concentration, 200 pM final), and 1 µl of
template DNA. The conditions for PCR were as follows: 94 ◦C for 3 min, with 35 cycles at
94 ◦C for 45 s, 50 ◦C for 60 s, and 72 ◦C for 90 s; with a final extension of 10 min at 72 ◦C.
The PCR amplicons were quantified using PicoGreen (Invitrogen) and a plate reader. Once
quantified, different volumes of each of the products were pooled into a single tube so that
each amplicon is represented equally. This pool was then cleaned up using UltraClean R©
PCR Clean-Up Kit (MoBio), and then quantified using the Qubit (Invitrogen). After
quantification, the molarity of the pool was determined and diluted down to 2 nM,
denatured, and then diluted to a final concentration of 6.75 pM with a 10% PhiX spike for
sequencing on the Illumina MiSeq. Sequence analysis was performed using mothur version
1.39.3 following the mothur MiSeq SOP available at the mothur website (Kozich et al.,
2013). Briefly, contigs were joinedwith ‘‘make.contigs’’, reads longer than 250 bp, harboring
any ambiguous bases or with more than 8 consecutive homopolymers were excluded using
‘‘screen.seqs’’. Chimeric sequences were removed with ‘‘chimera.uchime’’ and the reads
were clustered into operational taxonomic units (OTUs) using a 97% similarity threshold
and taxonomy was assigned to OTUs using the SILVA NR 128 reference database (Quast et
al., 2013). To identify biomarkers that differ in abundance between groups were done with
the LEfSe (Segata et al., 2011) implementation in mothur; for this, p-values <0.05 were
considered significant. As a first step, LEfSe performs a Kruskall-Wallis test to analyze all
features whether the values in different classes are differentially distributed. In a second
step, a pairwise Wilcoxon test is performed with the retained features. In the last step,
a linear discriminant analysis model is built from the retained features to determine the
effect sizes for each feature. For determination of differences between groups on the
community level, analysis of molecular variance (AMOVA) and analysis of similarity
(ANOSIM) implemented in mothur was used. Heatmaps were generated with JColorGrid
(Joachimiak, Weisman & May, 2006). For better taxonomic classification, the OTUs were
searched against the 16S rRNA gene sequences of the Mouse Intestinal Bacterial Collection
isolates (miBC; Lagkouvardos et al., 2016) using BlastN.
RESULTS
As can be seen in Fig. 1, animals administered 20 mg/kg body weight of fluoxetine over a
29-day dosing period evidence changes in body weight while those administered diluent
did not. This dosage, as previously discussed in the ‘Materials and Methods’ section, was
chosen based upon a landmark study examining the dose response relationship of chronic
per oral administration in three strains of mice and its ability to influence models of anxiety
and depression (Dulawa et al., 2004). In Fig. 1A, the ability of fluoxetine to differentially
increase or decrease weight in select animals is evident while such dramatic shifts were not
observed in any of the control animals. As shown in Fig. 1B, fluoxetine administration
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Figure 2 Relative abundance of bacterial phyla. The figure shows mean relative abundance values for
Firmicutes, Bacteroidetes, Tenericutes, and Proteobacteria in the control group and fluoxetine-treated mice.
Error bars represent standard error of the mean.
Full-size DOI: 10.7717/peerj.6199/fig-2
resulted in a statistically significant (p= 0.018, two-tailed t -test) change in weights gain/loss
during the first 15 days. This result has also been observed in humans and animal models
as administration of fluoxetine can lead to dramatic changes in weight (Anderson, 1998;
Cascade et al., 2010). Firmicutes were more abundant than Bacteroidetes in the fluoxetine
treated mice (Fig. 2). As such, there was no consistent change in one direction of weight
gain or loss that could be correlated with the Firmicutes/Bacteroidetes ratios which has
also been noted in humans (Sze & Schloss, 2016). This observation of fluoxetine-induced
changes in mice is also in agreement with observations in the human population that it
is a change in body weight, which could be either a gain or loss, which is experienced in
individuals administered given fluoxetine. Currently, there are no predictive measures for
the a priori prediction of the direction of the weight change.
As shown in Fig. 3, behavioral testing of mice tested at the end of the 29-day dosing
period revealed the development of mild anxiogenic-like behavior. For the EPM an increase
in entries into the closed arm (Fig. 3A; p= 0.047) as well as decreased time in the center
platform of the EPM (Fig. 3B; p= 0.030) were observed. For the OF an increase in total
number of rearings in all zones (Fig. 3C; p= 0.008), time rearing in the periphery zone
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Figure 3 Behavioral assessment of control (N = 10 per group) and fluoxetine-dosed (N = 10 per
group) mice at conclusion of 29-day dosing regimen. (A) Entries into closed arm of EPM; (B) time in
center platform of the EPM; (C) total rearings in all zones of the OF; (D) time rearing in the periphery
zone of the OF; (E) distance traveled in the periphery zone of the OF; and (F) time in the center zone of
the OF. Statistical analyses were conducted and p values are shown in the figure (two-tailed t tests).
Full-size DOI: 10.7717/peerj.6199/fig-3
(Fig. 3D; p= 0.009), distance traveled in the periphery (Fig. 3E; p= 0.042) were observed
while decreased time in the center zone (Fig. 3F; p= 0.035) was seen. These fluoxetine
anxiogenic-like induced effects are also consistent with what has been observed in human
and animal models (Aggarwal et al., 2016; Anderson, 1998; Cascade et al., 2010).
In total, 1.42 million reads were obtained after merging the forward and reverse reads.
After quality control, 1.134 million high quality reads remained which were clustered
into 1,612 OTUs with at least 10 reads. On phylum level, the microbiota of the mice in
this experiment was dominated by Firmicutes (51.4%), Bacteroidetes (44.8%), Tenericutes
(1.2%), and Deferibacteres (1.2%) (Fig. 2). All other phyla showed less than 1% relative
abundance among all samples.
The calculated species richness and diversity indicators were inconsistent and not
significantly different between the groups: Some animals showed an increase in species
richness and diversity during the trial, and others stayed similar or decreased (Table S1).
No significant differences (p> 0.57) were found in the richness and diversity estimators
between the control and the fluoxetine treated group. Most of the OTUs had highest
similarity to phylotypes described as members of the murine gastrointestinal tract (Fig. 4,
Tables S2, S3). Our results revealed clear differences in abundance of OTUs between the two
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groups. Among all OTUs, 121 OTUs were significantly different between control and the
fluoxetine group; 21 of these OTUs were among the 100 most abundant OTUs (Table S4).
Some Bacteroidales S24-7 group, some Lachnospiraceae OTUs and the LactobacillusOTU17
(the latter showed a 7.4-fold decrease under fluoxetine treatment) were significantly more
abundant in the control group, whereas the Alistipes OTU24, the Lachnoclostridium and
Anaerotruncus OTUs were more abundant in the fluoxetine-treated mice.
On the genus level, Bacteroidales S24-7 group, unclassified Lachnospiraceae, and
Lachnospiraceae_NK4A136 group were most abundant (Fig. 5). Similar to our findings on
OTU level, a genus belonging to the Bacteroidales S24-7 group and genera affiliating
to the Ruminococcaceae_UCG-014 group were significantly more abundant in the
control group (Table S5). Genera affiliating to the Lachnospiraceae_UCG-001 and UCG-
006 groups, to Anaerotruncus, Lachnoclostridium and to uncultured Lachnospiraceae
showed significantly higher abundance in the fluoxetine treated mice. In addition, also
Anaerotruncus, Ruminiclostridium_5, unclassified Coriobacteriaceae, and Lachnoclostridium
were significantly more abundant in the fluoxetine treated mice. Comparisons on whole
community level using AMOVA and ANOSIM revealed significant differences between the
microbial communities of the control group and the fluoxetine treated mice (p= 0.02 and
p= 0.05, R= 0.28, respectively).
DISCUSSION
Overall, our data revealed significant differences between the microbial communities of
mice from the control group compared to the fluoxetine treated mice indicative of a
shift of microbial communities towards dysbiosis induced by the fluoxetine treatment. As
discussed in prior sections, we chose to administer a chronic dose of fluoxetine (20 mg
per kg of body weight) that had been previously shown in a landmark study examining
the dose response relationship of chronic fluoxetine administration in four strains of mice
to be the only one active in all employed models of anxiety and depression (Dulawa et al.,
2004). Specifically, a dose response range from 0 to 25mg per kg body weight was employed
with the finding that 18 mg per kg was the only dosage found effective in all behavioral
paradigms (Dulawa et al., 2004). As can be seen in Fig. 1, statistically significant changes
in bodyweight occurred during the first 15 days of administration that closely mimic what
is observed in humans and other animal models. Such dramatic shifts in weight gain/loss
are often cited as a primary reason for patient non-compliance in continuing drug therapy
(Anderson, 1998; Cascade et al., 2010). The ability of this chronic dose of fluoxetine to
influence standard measures of anxiety-like behavior in mice was also observed (Fig. 3) as
has been noted in other studies which have employed chronic administration of similar
levels of per oral administered fluoxetine (Dulawa et al., 2004; Gosselin et al., 2017).
The bioinformatic analyses examining the ability of fluoxetine to influence the
composition of the microbial communities demonstrated novel effects not previously
reported in the literature. Most strikingly, the analyses revealed that some OTUs were
significantly higher abundant in the control group, such as several Bacteroidales S24-7
group OTUs and one Lactobacillus OTU. Recently, an inhibition of growth of Lactobacillus
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Figure 4 Relative abundance of the 30 most abundant OTUs. The heatmap shows median relative
abundance values for OTUs in the control group and fluoxetine-treated mice. OTUs which were
statistically significantly different between the two groups based on LEfSe (Segata et al., 2011) are
highlighted in bold and by asterisks (see Table S4 for details).
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cally significantly different between the two groups based on LEfSe (Segata et al., 2011) are highlighted in
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Full-size DOI: 10.7717/peerj.6199/fig-5
by fluoxetine has been described (Cussotto et al., 2018) and Lactobacillus treatment reduced
depressive-like behavior (McVey Neufeld, Kay & Bienenstock, 2018). It should be noted that
not all LactobacillusOTUs in our study decreased due to the fluoxetine treatment. This could
suggest that the fluoxetine treatment might affect different Lactobacillus strains or species
differently. This differential effect of fluoxetine on lactobacilli is especially intriguing in light
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of the reports that demonstrate that specific species and strains, such as L. reuteri (Marin et
al., 2017) and L. rhamnosus JB-1 (McVey Neufeld, Kay & Bienenstock, 2018) can influence
behavior, while other lactobacilli cannot (Bravo et al., 2011; Vancanneyt et al., 2006). A
number of OTUs and genera were significantly more abundant in the treatment group
included Alistipes, various Lachnospiraceae OTUs, Lachnoclostridium and Anaerotruncus.
Alistipes belongs to the Bacteroidetes and is often found in murine gastrointestinal tract
microbiota samples (Lagkouvardos et al., 2016). Alistipes have recently been found to be
increased in abundance in patients with gastrointestinal complications after thoracic aortic
dissection surgery (Zheng et al., 2017), and are reported to be associated with human
colorectal carcinoma (Shi et al., 2017). Alistipes have been shown to induce colitis and
tumors in mice (Moschen et al., 2016) and were increased in mice exposed to ethanol
(Peterson et al., 2017). Alistipes OTU24 might thus be an indicator of gastrointestinal
dysbiosis. However, other Alistipes OTUs found in this study (e.g., OTUs 23, 25, 47) did
not reveal significant differences in abundance between the two experimental groups. A
recent study has shown that Alistipes was reduced in abundance in mice in response to
chemically or pathogen induced colitis and this study indicated that Alistipes is particularly
sensitive to inflammation and possesses butyrate production capacity (Borton et al., 2017).
This suggests that different phylotypes/OTUs within a genus or family can possess different
metabolic properties as suggested earlier (Berry et al., 2012). Anaerotruncus is a genus in the
Firmicutes, the function of its members remains largely unknown. Bacteria affiliating to the
genus Anaerotruncus have been isolated from fecal samples from patients with obesity or
malnutrition (Pham et al., 2017;Togo et al., 2016) and have been associatedwith bacteremia
in humans (Lau et al., 2006). Furthermore, Anaerotruncus was increased in rats exposed to
prenatal stress (Golubeva et al., 2015). These data indicate that Anaerotruncus may be an
indicator of gastrointestinal dysbiosis. SeveralOTUs affiliating to theLachnospiraceae family
(OTUs 32, 38, 86, 93) were significantly more abundant in the fluoxetine treated mice. Our
knowledge about the metabolic properties of many members of the Lachnospiraceae is still
limited. A recent study has revealed members of unclassified Lachnospiraceae as important
drivers of gastrointestinal dysbiosis in mice (Moschen et al., 2016).
Three OTUs affiliating the genus Roseburia (OTUs 45, 69, 74) showed significant
differences between the two conditions. Two of these OTUs (45 and 74) were more
abundant in the fluoxetine treatedmice, whereas OTU69 wasmore abundant in the control
group. In general, Roseburia is considered a beneficial commensal bacterium producing
butyrate and having a positive impact on the host immune system and the abundance of
Roseburia has been reported to decrease under various disease conditions (Patterson et al.,
2017; Tamanai-Shacoori et al., 2017). However, recently, a higher abundance of Roseburia
was linked to gut dysbiois in mice and to cerebral hypometabolism (Sanguinetti et al.,
2018). The higher abundance of Roseburia OTUs 45 and 74 in the fluoxetine treated mice
provides preliminary evidence that drug-induced changes in microbial communities may
be a contributing factor in the development of altered physiology.
OTU46 is assigned to the genus Lachnoclostridium comprising members of the
Clostridum cluster XIV including the former Clostridium scindens (Yutin & Galperin,
2013) and shows 99% 16S rRNA gene similarity with C. scindens ATCC35704. Several
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C. scindens and related Clostridum species are able to convert primary bile acids to toxic
secondary bile acids such as deoxycholic acid and lithocholic acid which have been linked
to diseases of the gastrointestinal tract such as liver and colorectal cancer (Ridlon et al.,
2016). We thus speculate that the increase of OTU46 in the fluoxetine treated mice is a
sign of dysbiosis, possibly by the production of toxic secondary bile acids.
The most abundant OTUs and genus found in this study belong to the Bacteroidales
S24-7 group, including the recently described Muribaculum intestinale (Lagkouvardos et
al., 2016). Members of the Bacteroidales group S24-7 are highly abundant particularly
in murine and human gastrointestinal tract samples (Borton et al., 2017; Lagkouvardos
et al., 2016; Ormerod et al., 2016). Both on OTU and genus level, Bacteroidales S24- 7
showed higher abundance in the control group samples. Recent evidence shows that
members of the Bacteroidales S24-7 group are able to produce propionate and have mucin
degrading capacity (Borton et al., 2017;Ormerod et al., 2016) suggesting a beneficial role for
gastrointestinal tract health. In line with this, a reduction of the Bacteroidales S24-7 group
has been described recently in colitic and obese mice (Huazano-Garcia, Shin & Lopez, 2017;
Osaka et al., 2017). Furthermore, Bacteroidales S24-7 are reduced in mice prone to develop
dementia, suggesting a possible link of Bacteroidales S24-7 with normal brain function
(Sanguinetti et al., 2018).
The study by Cussotto et al. (Cussotto et al., 2018) showed that Prevotella and
Scuccinivibrio are decreased by fluoxetine. In our study, we did not identify Prevotella
or Succinivibrio among the 100 most abundant OTUs, which may be explained by different
experimental settings between the two studies such as different fluoxetine concentrations
and different animals (rat and mice).
The governing hypothesis in the present manuscript is based on the shared
neurochemistry between microbes and host, what has become known as microbial
endocrinology (Lyte, 2014). As shown, we have obtained the first data demonstrating
that microbiota belonging to a specific genera, such as Lactobacillus, and which have
previously been shown to possess the biogenic amine transporters PMAT and OCT (Lyte
& Brown, 2018), can be influenced by administration of an SSRI. It should however, be
noted that the genes encoding the Lactobacillus PMAT and OCT transporters have not
been identified yet. The ability of fluoxetine to affect the abundance of the other genera
discussed above raises the possibility that theymay also possess biogenic amine transporters
similar to that of Lactobacilli. Our lab is currently examining this possibility, but research
is hampered by the fact that representative members of fluoxetine-affected genera in this
study are not available in microbial culture collections. The physiological role of PMAT-
and OCT-like transporter activity in Lactobacilli is not yet understood.
It is critical to separate the results, and implications, of the present study from that of
others in which direct antimicrobial effects of SSRIs were observed (Munoz-Bellido, Munoz-
Criado & Garcia-Rodriguez, 1996; Munoz-Bellido, Munoz-Criado & Garcia-Rodriguez,
2000). In those studies, antimicrobial effects were observed in an in vitro assay system
where there was no possibility for concentrations of fluoxetine that exceed what can
be achieved in vivo to be eliminated. Further, bacterial genera that were observed to be
susceptible to mM concentrations of fluoxetine, such as Escherichia, were not observed
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to be decreased in the present study. As such, the working hypothesis is that fluoxetine is
exerting its effects through a PMAT- and OCT-like transporter in affected genera for which
the precise physiological role of this transporter has yet to be defined. The present data
conclusively demonstrates a genus-specific effect of fluoxetine that cannot be understood
in the context of solely antimicrobial activity for which concentrations needed to achieve
an either bacteriostatic or bactericidal effect need to be much higher than those that can
be achieved in the gut. Given the recent publication which has shown that in humans the
administration of antipsychotics disrupts fecal microbial diversity (Maier et al., 2018), it is
of importance to understand the mechanisms by which such alterations occur and if they
impact drug efficacy.
The role of the microbiota, and community structure, in determining behavior has
come under increasing investigation (Foster et al., 2016). A bi-directional axis involving the
microbiota, gut and brain has been proposed in which the microbiota influence behavior,
although mechanistic studies are still severely lacking. The need for identification of
mechanisms will be crucial if the concept of a microbiota-gut-brain axis is to progress
especially as regards eventual clinical application. The present study has shown that a
microbial endocrinology-based mechanism, namely on involving the PMAT- and OCT-
like biogenic amine transporters, may be one of the mechanisms responsible. The observed
differential changes in the abundance of specific microbiota genera that are well correlated
(as has been discussed above) with gut dysbiosis, suggests that the well-recognized negative
side effects of fluoxetine may be due to changes in gut microbiota that are mediated
via a bacterial biogenic amine transporter. The results of this study further suggest that
restoration of physiologically beneficial microbial diversity may have therapeutic potential
to ameliorate some of the negative side effects of fluoxetine thereby increasing drug efficacy
and patient compliance.
CONCLUSIONS
The present study has demonstrated that mice per orally administered fluoxetine exhibit
specific alterations in microbial community structure concomitant to alterations in body
mass as well as the development of mild anxiogenic-like behavior. As this study was
undertaken to examine the possible role of the microbiota as a contributing factor in the
development of the unwanted side effects with the use of fluoxetine in the treatment of
anxiety-related illness in humans, this report has provided first known initial evidence
for the involvement of a specific genus, Lactobacillus, that is also known to be involved
in regulation of body mass. Further, as prior work has shown that Lactobacilli possess a
biogenic amine transporter capable of incorporating fluoxetine (Lyte & Brown, 2018), it is
proposed that a microbial endocrinology-based specific mechanistic pathway is, in part,
responsible for the fluoxetine-induced weight alterations. By demonstrating the ability of
fluoxetine to affect the microbial community structure in a defined manner, the possibility
that restoration of normal structure through the use of probiotics may provide a means by
which the negative clinical side effects of fluoxetine leading to patient non-compliance in
the treatment of depression may be ameliorated.
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